NIFTY 50▲25,383.75
27.25 (0.11%)
SENSEX▲82,988.78
97.84 (0.12%)
NIFTY BANK▲52,153.15
215.10 (0.41%)
TATA MOTORS▼988.40
-3.70 (-0.37%)
SUZLON ENERGY▲84.70
1.59 (1.91%)
INDIAN RAILWAY FINANCE CORP▼163.96
-3.29 (-1.97%)
TATA STEEL▲154.21
0.72 (0.47%)
TATA POWER▲443.35
1.55 (0.35%)
RAIL VIKAS NIGAM▼545.30
-10.00 (-1.80%)
INDIAN RENEWABLE ENERGY▼228.39
-3.20 (-1.38%)
RELIANCE INDUSTRIES▼2,942.70
-2.55 (-0.09%)
VODAFONE IDEA▼13.24
-0.17 (-1.27%)
ZOMATO▲277.70
4.80 (1.76%)
ADANI POWER▲665.95
32.50 (5.13%)
YES BANK▲23.50
0.20 (0.86%)
NHPC▲96.19
1.91 (2.03%)
RELIANCE POWER▲31.05
1.22 (4.09%)
STATE BANK OF INDIA▼785.55
-5.30 (-0.67%)
HDFC BANK▲1,670.95
5.00 (0.30%)
JIO FIN SERVICES LTD▼348.80
-3.10 (-0.88%)
ADANI PORT & SEZ▼1,440.70
-11.40 (-0.79%)
BHARAT ELECTRONICS▲290.40
0.45 (0.16%)
GTL INFRA▼2.49
-0.07 (-2.73%)
INDIAN OIL CORP▼171.82
-1.37 (-0.79%)
MRF▼1,36,250.00
-1103.95 (-0.80%)
OLA ELECTRIC MOBILITY LTD▼107.60
-3.98 (-3.57%)
INDIAN RAILWAY TOURISM CORP▼935.75
-1.15 (-0.12%)
RATTANINDIA POWER▲15.43
0.14 (0.92%)
Sun Pharma Advanced Research Share Price
SPARC
₹224.57-₹1.49 (-0.66%) TodayLast updated on 16 Sep, 2024 | 15:56 IST
Please wait...
What’s in news?
Company overview
Financial performance
Market cap
| Open₹227.30 | Close₹226.06 |
Circuit range₹271.27 - ₹180.84 | Day range₹223.40 - ₹227.65 | Year range₹196.10 - ₹472.80 |
Volume2,99,462 | Avg. traded₹225.03 | Revenue (12m)₹68 Crs |
Sun Pharma Advanced ResearchSun Pharma Advanced Research Company Limited is an India-based clinical-stage biopharmaceutical company that focuses on developing therapeutics to improve standards of care for patients worldwide. The Company’s therapeutic focus is in the area of oncology, neurology and immunology. Its lead oncology programs include vodobatinib (SCO-088), a BCR-ABL targeting tyrosine kinase inhibitor for refractory chronic myelogenous leukemia, and an anti-MUC-1 antibody-drug conjugate (ADC) with the potential to treat multiple cancers. Its lead therapeutic agent, vodobatinib (SCC-138), is a c-ABL inhibitor that has the potential to be a therapy modulating cellular homeostasis in neurodegenerative diseases. Vibozilimod (SCD-044) is a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist targeting autoimmune disorders. SCD-153 is a topical agent being developed for the treatment of alopecia areata. SBO-154 is an ADC being developed for multiple tumor types expressing MUC-1.
Sun Pharma Advanced Research Key indicators
52 week high₹472.80 | 52 week low₹196.10 | P/E ratio |
P/B ratio243.6 | ROE-121.73% | ROCE-112.88% |
Dividend yield-- | Debt/Equity ratio0.38 | EPS-11.96 |
Learn more
Investment checklist: (1/6)
Equity returns
Dividend returns
Safety factor
Growth factor
Debt vs Equity
Profit factor
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily
Analyst ratings:
Analyst ratings:
100%
Hold
0%
Sell
0%
This analysis is based on the reviews of 1 experts in the last 7 days
Fundamentals
Financial ratios
Operating profit margin-495.49% | Net profit margin-513.74% |
ROE-121.73% | ROA-58.96% |
ROCE-112.88% |
Learn more
Sun Pharma Advanced Research Share Price history
Day | Open | Close | Day’s change |
---|---|---|---|
Fri, Sep 13 2024 | ₹226.75 | ₹226.06 | |
Thu, Sep 12 2024 | ₹226.00 | ₹225.36 | |
Wed, Sep 11 2024 | ₹231.00 | ₹224.12 | -2.93% |
Tue, Sep 10 2024 | ₹235.49 | ₹230.89 | -0.06% |
Mon, Sep 9 2024 | ₹225.72 | ₹231.02 | |
Fri, Sep 6 2024 | ₹228.50 | ₹225.72 | |
Thu, Sep 5 2024 | ₹226.90 | ₹224.54 | -0.54% |
Wed, Sep 4 2024 | ₹220.77 | ₹225.76 |